Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

被引：2
|
作者：
Tefferi, Ayalew [1 ]
Pardanani, Animesh [1 ]
Gangat, Naseema [1 ]
机构：
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 08期
关键词：
HYDROXYUREA; MUTATIONS; THERAPY; CALRETICULIN; RUXOLITINIB; JAK2(V617F); TRIAL; AGE;
D O I：
10.1002/ajh.27375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1459 / 1461
页数：3
相关论文
共 50 条
  • [41] The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
    Deininger, Michael
    Radich, Jerald
    Burn, Timothy C.
    Huber, Reid
    Paranagama, Dilan
    Verstovsek, Srdan
    BLOOD, 2015, 126 (13) : 1551 - 1554
  • [42] Gender Determines the Myeloproliferative Neoplasms Phenotype Independently of Age, Driver Mutation and JAK2V617F Burden
    Karantanos, Theodoros
    Chaturvedi, Shruti
    Karanika, Styliani
    Braunstein, Evan
    Resar, Linda
    Spivak, Jerry
    Moliterno, Alison
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S267 - S268
  • [43] An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms
    Moraes, Graciela Rabadan
    Pasquier, Florence
    Marzac, Christophe
    Deconinck, Eric
    Damanti, Carlotta Caterina
    Leroy, Gwendoline
    El-Khoury, Mira
    El Nemer, Wassim
    Kiladjian, Jean-Jacques
    Raslova, Hana
    Najman, Albert
    Vainchenker, William
    Marty, Caroline
    Bellanne-Chantelot, Christine
    Plo, Isabelle
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 131 - 136
  • [44] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes, Raoul
    Mesa, Ruben A.
    LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
  • [45] Interleukin-1β, JAK2V617F mutation and inflammation in MPNs
    Hermouet, Sylvie
    Hasselbalch, Hans C.
    BLOOD ADVANCES, 2024, 8 (16) : 4344 - 4347
  • [46] Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms
    Mullally, A.
    PATHOLOGE, 2016, 37 : 175 - 179
  • [47] Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
    Verger, Emmanuelle
    Soret-Dulphy, Juliette
    Maslah, Nabih
    Roy, Lydia
    Rey, Jerome
    Ghrieb, Zineb
    Kralovics, Robert
    Gisslinger, Heinz
    Grohmann-Izay, Barbara
    Klade, Christoph
    Chomienne, Christine
    Giraudier, Stephane
    Cassinat, Bruno
    Kiladjian, Jean-Jacques
    BLOOD CANCER JOURNAL, 2018, 8
  • [48] Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
    Lussana, Federico
    Carobbio, Alessandra
    Salmoiraghi, Silvia
    Guglielmelli, Paola
    Vannucchi, Alessandro Maria
    Bottazzi, Barbara
    Leone, Roberto
    Mantovani, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 8
  • [49] Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model
    Alves-Silva, Antonio Bruno
    Fenerich, Bruna Alves
    Fonseca, Natasha Peixoto
    Fernandes, Jaqueline Cristina
    Coelho-Silva, Juan Luiz
    Pereira-Martins, Diego Antonio
    Bianco, Thiago Mantello
    Scheucher, Priscila Santos
    Rego, Eduardo Magalhaes
    Chahud, Fernando
    Machado-Neto, Joao Agostinho
    Figueiredo-Pontes, Lorena Lobo
    Traina, Fabiola
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (03) : 576 - 585
  • [50] Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
    Federico Lussana
    Alessandra Carobbio
    Silvia Salmoiraghi
    Paola Guglielmelli
    Alessandro Maria Vannucchi
    Barbara Bottazzi
    Roberto Leone
    Alberto Mantovani
    Tiziano Barbui
    Alessandro Rambaldi
    Journal of Hematology & Oncology, 10
12345